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Chronic myelogenous leukemia (CML) is a hematological malignancy that expresses the BCR-ABL fusion oncogene. It has three distinct clinicopathological phases: chronic phase, accelerated phase and blast crisis. Tyrosine kinase inhibitors, which target the BCR-ABL fusion protein, can induce complete cytogenic remission in more than 70% of newly diagnosed chronic CML patients. However, complete molecular response is a rare event in these CML patients with complete cytogenic remission, suggesting that they are not effective in eliminating CML leukemia-initiating cells (LIC), although there are differences between the trosine kinase inhibitors. Once CML progresses to blast crisis, it becomes resistant to most treatment approaches, and survival rapidly declines. The exact underlying mechanism of transformation of chronic phase CML to blast crisis is still unclear; however, it is thought to be supported by self-renewing LIC. Therefore, identifying genes or signaling pathways involved in the self-renewal of LIC may promote more effective leukemia treatments. So far, two key regulators in self-renewal of LIC have been linked to CML progression, Wnt/ b-catenin and Bmi-1. [1] [2] [3] [4] Recently, several research groups, including ours, have demonstrated that SALL4 has an essential role in the maintenance of pluripotent and self-renewal properties of embryonic stem cells by interacting with Nanog and Oct4. 5 In addition, our group has shown that constitutive expression of SALL4 contributes to leukemogenesis in adult mice by interacting with two other key regulators in LIC, Wnt/b-catenin and Bmi-1. 6, 7 It seems that SALL4 is a unique gene involved in self-renewal in embryonic stem cells and LIC. Therefore, we examined SALL4 expression in CML to determine whether it could be involved in the pathogenesis of this disease. 
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Using immunohistochemistry staining, we observed that SALL4 expression was present in blast-crisis CML (9/12, 75%) but not in chronic phase (0/11, 10%). In accelerated phase (1/6, 16.7%), wherein the blast count was 10-19%, immature blasts expressing SALL4 were observed in a background of negative, more mature myeloid cells (Figure 1a) . Similar results were observed when we carried out fluorescence-activated cell sorting (FACS) analysis on whole bone-marrow cells from normal human and CML samples at different disease phases using a conjugated SALL4 antibody (Figure 1b) . No SALL4-positive population was detectable in normal whole bonemarrow or chronic phase CML samples. A distinct SALL4-positive population was present in accelerated phase and blast-crisis CML marrows, which correlated well with the blast count and overlapped with the CD34 þ population. The CD34 þ CD38 þ cells had the highest SALL4 RNA expression, when tested by quantitative reverse-transcription PCR (qRT-PCR) (Figure 1c and Supplementary Table 1 ). This finding is of particular interest as Granulocyte-Macrophage Progenitors, which are CD34 þ CD38 þ , have been proposed as candidate LIC in CML, which transforms to acute myeloid leukemia. 1 To explore the role of SALL4 in CML, we first tested whether overexpression of SALL4B could block myeloid differentiation and cooperate with BCR-ABL in, consequently, promoting blastic transformation of chronic phase CML. For induction of CML-like leukemia, we harvested bone marrow cells from SALL4B transgenic and wild-type (WT) donor mice by giving 4 days post-intravenous administration of 200 mg per kg (body weight) 5-fluorouracil (5-FU), transduced with BCR-ABL-GFP retrovirus as described, 8 and injected 4 Â 10 5 cells intravenously into sublethally irradiated (750cGy) C57BL/6 recipients. Slightly sublethal irradiation in this mouse model has been shown not to inhibit induction of CML-like disease. Both, recipients of BCR-ABL induced SALL4B transgenic and WT bone marrow, succumbed to fatal CML-like leukemia within 3-6 weeks with increased WBC counts (Supplementary Table 2 ). Flow-cytometry analysis demonstrated that 80% of BCR-ABL-positive bone marrow cells from both groups were Mac1 þ and Gr-1 þ neutrophils (Supplementary Figure 1A) . In addition, the percentage of CD34 þ or c-Kit BCR-ABL-positive cells from bone marrow and spleen increased about two and threefold in leukemic SALL4B transgenic recipients compared with WT counterparts (Supplementary Figures 1B and 1C and data not shown). This suggests that BCR-ABL-transduced SALL4B leukemic cells were more immature and less differentiated.
We next investigated the functional role of SALL4 in CML progression using a loss-of-function approach by knocking down SALL4 expression in the human CML cell line KBM5. Two small hairpin RNA retroviral constructs targeting different regions of the SALL4 mRNA as we previously reported, 6 were shown by qRT-PCR to reduce SALL4 and Bmi-1 mRNA level in KBM5 cells (Figure 2a) . The KBM5 cells expressing reduced levels of SALL4 grew slowly. To better explain this phenomenon, we measured the level of caspase-3, which is a marker for the apoptosis-signaling pathway. In KBM5 cells that retained 50% of the WT levels of SALL4, there was a threefold increase of caspase-3 activity from 27.9% in WT cells to 93.6% in cells with reduced SALL4 levels as measured by FACS (Figure 2b) .
We have previously shown that Bmi-1 is a major downstream target of SALL4 in leukemic cells. 6 To determine whether overexpression of Bmi-1 could rescue SALL4-induced apoptosis, we transfected SALL4 small hairpin RNA-treated KBM5 cells with an expression vector containing Bmi-1. As shown in Figure 2b , SALL4-induced caspase-3 activity (Figure 2b -ii) was restored to a near normal level by overexpression of Bmi-1 (Figure 2b-iii) .
To further study the role of SALL4 in cell growth in a leukemic cell line, we monitored cell-cycle changes and cellular DNA synthesis in SALL4-reduced and WT KBM5 cells using the BrdU incorporation assay by FACS. A 50% reduction of SALL4 expression level in KBM5 cells resulted in G 0 /G 1 phase (37.8%) and G2 phase (21.7%) arrests (Figure 2c-ii) . A more than twofold decrease in S phase cells was also observed, paralleling the drop in DNA synthesis measured by the level of BrdU incorporation. In contrast, no significant change in the cell-cycle profile was observed when WT KBM5 cells were infected with control viruses (Figure 2c-i) . Reintroduction of Bmi-1 in SALL4-reduced KBM5 cells can rescue this phenotype (Figure 2c-iii) .
Our data suggest that the stem cell factor SALL4 has an important role in the proliferation and survival of CML cells, and its expression is associated with an advanced stage of CML disease. The mechanism of SALL4-mediated proliferation and survival of CML cells, at least in part, is mediated by the Bmi-1 pathway. In support of this concept, downregulation of SALL4 leads to apoptosis and cell-cycle arrest in CML cells, which is rescued by restoring its downstream target gene Bmi-1. This finding suggests that targeting SALL4 may provide a novel therapeutic modality for advanced-stage CML disease.
An exclusive production of light chains can be found in B15% of myeloma cases, and in these light-chain multiple myeloma (LC-MM) cases, the phenotype remains unchanged throughout subsequent progression and relapse. Once established, it suggests that this phenotype is maintained by the 'feeder cell' that re-populates the tumor bulk as disease re-emerges. This raises an important question of what the nature of the 'feeder cell' is that perpetuates disease, a question of wider relevance in multiple myeloma (MM), and how the 'feeder cell' is derived from the cell of origin that gives rise to disease.
In defining the cell of origin in MM and other B-cell tumors, immunoglobulin (Ig) variable (IGV) region gene analyses have provided important insights, relying on well-defined events in normal B-cell maturation to establish clonal history. In normal B-cells, IGV assembly occurs early with signature CDR3 motifs 1 to constitute functional sIg molecules, allowing exit from the bone marrow (BM). These peripheral B-cells, on recognizing antigen via sIg in secondary lymphoid follicles initiate the germinal center reaction and undergo somatic hypermutation (SHM) of IGV genes. Deletional isotype class switch recombination (CSR) at the chromosome 14q32 locus can also occur in germinal centers to alter effector function. 2 IGV analysis can track such events as they relate to malignant B-cell origins.
